Medical device and MedTech insights, news, tips and more

CVS Announces a Cheap Generic Alternative to EpiPen

January 24, 2017

Epipen

Epipen

Pharmaceutical giant CVS announced Thursday that it has partnered with Impax Laboratories to sell a generic epinephrine auto-injector for $109.99 for a two-pack—a dramatic cut from Mylan’s Epipen two-pack prices, which list for more than $600 as a brand name and $300 as a generic.

The lower-cost auto-injector, a generic form of Adrenaclick, is available starting today nationwide in the company’s more than 9,600 pharmacies. Its price resembles that of EpiPen’s before Mylan bought the rights to the life-saving devices back in 2007 and raised the price repeatedly, sparking outcry.

Helena Foulkes, president of CVS Pharmacy, said the company felt compelled to respond to the urgent need for a more affordable alternative. “Over the past year, nearly 150,000 people signed on to a petition asking for a lower-cost epinephrine auto-injector option and millions more were active in social media searching for a solution,” she said in a statement.

The price of $109.99 for the alternative applies to those with and without insurance, CVS noted. And Impax is also offering a coupon to reduce the cost to just $9.99 for qualifying patients.

Also in the press statement, Dr. Todd Listwa of Novant Health, a network of healthcare providers, noted the importance of access to epinephrine auto-injectors, which swiftly reverse rapid-onset, deadly allergic reactions in some. “For these patients, having access to emergency epinephrine is a necessity. Making an affordable epinephrine auto-injector device accessible to patients will ensure patients have the medicine they need, when they need it.”

Last year, Mylan came under heavy fire from the public and lawmakers for the soaring cost of its devices, as well as allegedly cheating Medicaid out of millions and using anti-competitive practices to set up deals with school systems.

Read Full Article – Source: CVS just announced a super cheap generic alternative to EpiPen | Ars Technica

Author – Beth Mole

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.